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The cancer stem cell (CSC) hypothesis in its original form 
postulates that a small subpopulation of cancer cells is responsible for 
propagation of the tumor [1]. By comparison to normal stem cells, 
CSCs are predicted to be drug-resistant due to increased expression of 
proteins such as anti-alkylating enzymes like aldehyde dehydrogenase 
(ALDH) that neutralize the therapeutic agents [2] or members of the 
ATP-binding cassette (ABC) family of transporters that efflux them out 
of the cells [3].
Multiple myeloma (MM) is an incurable malignancy of B-lymphoid 
cells characterized by the accumulation of differentiated plasma cells in 
the bone marrow. MM is responsible for over 30,000 deaths each year 
in the United States and the European Union. While patients initially 
respond to therapy, they eventually relapse because the MM cells 
acquire drug resistance [4].
Demonstration of a low percentage of clonogenic cells in the bulk 
tumor mass prompted a search for the CSC in MM [5]. But contradictory 
results have been obtained regarding the phenotype of the proposed 
tumor-propagating cells; moreover, the relationship between drug-
resistant MM cells at relapse and putative MM CSCs remains a matter of 
much debate [6-18]. A subpopulation of clonogenic MM cells has been 
described having a memory B cell-like phenotype (CD19+CD20+CD27+) 
[6]. Although CD19+CD20+CD27+ MM cells lacked the characteristic 
plasma cell antigen CD138, they were capable of differentiating into 
CD138+ plasma cells [7]. These studies suggested that MM is organized 
in a hierarchical manner and that CD19+CD20+CD27+ MM cells might 
represent a putative MM CSC [19] . However, other work indicates 
that such cells might represent a premalignant intermediate [20]. 
Their biological significance has also been questioned based on their 
rarity. For example, one study investigating the clonal hierarchy in 
light chain MM was unable to confirm the presence of tumor-specific 
immunoglobulin sequences in the memory B cell compartment [10]. A 
number of other recent reports have also failed to obtain evidence in 
support of this supposition [13,14,16]. These latter results are consistent 
with the prevailing assumption that neoplastic transformation in MM 
occurs at a post-memory B cell stage when somatic hypermutation of 
immunoglobulin genes has ceased [21,22]. 
Various strategies have been employed to prospectively isolate and 
study CSC-like tumor-propagating cells. One common approach is 
based on the expression of cell surface markers that are characteristic 
of the stem cell phenotype of the corresponding normal tissue. An 
example of this approach involves expression of the CD34 cell surface 
marker of immature hematopoietic cells (see [23] for review). It is of 
interest in this regard that a subpopulation of CD138+ MM cells has 
been reported to express CD34 [8].
Another approach capitalizes on the functional properties of stem 
cells. As noted above, stem cells are highly resistant to damage by toxic 
agents through a combination of mechanisms [2,3,24,25]. Some of 
these attributes can be exploited by flow cytometry-based procedures 
to enrich for stem-like cells [23,26]. Efflux of the vital dye Hoechst 
33342 by the ABCG2 and/or ABCB1 transporters identifies a subset 
of cells in a variety of normal and malignant tissues—termed “side 
population” (SP) cells—which displays stem cell-like properties [27,28]. 
Interestingly, variable results have also been obtained concerning 
the SP phenotype in human MM cell lines and patient samples. 
Using this assay, one group identified a clonogenic CD138neg MM 
subpopulation that was resistant to the anti-MM agent lenalidomide 
[7] whereas another group subsequently described the characterization 
of clonogenic SP cells in MM that primarily expressed CD138 and 
were sensitive to lenalidomide [9]. Likewise, ALDH has been shown 
to be a marker of CSC-like cells in a wide range of tumors, including 
the B-lymphoid malignancies Hodgkin lymphoma and mantle cell 
lymphoma [29,30]. Although it has been reported that certain MM cell 
cultures as well as patient samples contained subpopulations of ALDH+ 
cells with a CSC-like phenotype [7,18], the generality of this finding has 
been questioned [17].
How can these discrepant observations be reconciled? On the 
one hand, it is important to appreciate that MM is characterized by 
significant molecular heterogeneity, comprising at least seven disease 
subtypes [31]. A potential scenario that could also help to integrate 
the incongruent observations would be if malignant transformation 
of CD138+ post-memory B cells results in the acquisition of a CSC-
like phenotype [32], e.g., by a “dedifferentiation” mechanism that is 
akin to the cellular reprogramming that occurs during the generation 
of induced pluripotent stem cells [22,33,34]. Indeed, activation of the 
MYC proto-oncogene, one of four transcription factors used in the 
initial reprogramming experiments [35], is a recurring event in MM 
pathogenesis [36]. 
Thus, the putative MM CSC would not be expected to be a single 
genetic entity; rather, genetically-distinct subtype-associated CSCs are 
predicted. Furthermore, it would not be surprising if MM CSCs exhibit 
phenotypic variability during tumor progression as a result of epigenetic 
changes and genomic instability [37]. Considered in this light, it will be 
a challenging task but well worth the effort to delineate all of the MM 
CSC subpopulations. The clinical implications are profound in that 
subtype-specific concerted therapies targeting the bulk as well as the 
various CSC fractions of the tumor will undoubtedly be necessary if an 
effective cure is to be found for this devastating collection of diseases.
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